Recommendations of the treatment-resistant depression expert center network for promoting tobacco smoking cessation based on the results from the real-world FACE-TRD national cohort.
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2022-03-01; 114: 110479
DOI: 10.1016/j.pnpbp.2021.110479
Lire sur PubMed
1. Prog Neuropsychopharmacol Biol Psychiatry. 2022 Mar 2;114:110479. doi:
10.1016/j.pnpbp.2021.110479. Epub 2021 Nov 23.
Recommendations of the treatment-resistant depression expert center network for
promoting tobacco smoking cessation based on the results from the real-world
FACE-TRD national cohort.
Korchia T(1), Faugere M(1), Suc N(2), Garosi A(1), Andrieu-Haller C(1), Breyton
M(1), Godin O(3), Aouizerate B(4), Arbus C(2), Bennabi D(5), Bellivier F(6),
Bougerol T(7), Camus V(8), Courtet P(9), Doumy O(4), El-Hage W(10), Genty
JB(11), Haffen E(5), Holtzmann J(7), Horn M(12), Leboyer M(11), Llorca PM(13),
Maruani J(6), Moirand R(14), Moliere F(9), Petrucci J(11), Rey R(14), Samalin
L(13), Stephan F(15), Vaiva G(16), Walter M(15), Yrondi A(2), Boyer L(17),
Lancon C(1), Richieri R(1), Fond G(18); FondaMental Advanced Centres of
Expertise in Resistant Depression (FACETRD) Group.
Author information:
(1)Fondation FondaMental, Creteil, France; Aix-Marseille university, AP-HM,
Academic department of psychiatry, Resistant Depression Expert Center
(FondaMental Foundation), CHU La Conception, Marseille, France.
(2)Fondation FondaMental, Creteil, France; Service de Psychiatrie et de
Psychologie Médicale de l’adulte (Department of Psychiatry and Adult Medical
Psychology), Centre Expert Dépression Résistante FondaMental (FondaMental
Advanced Centre of Expertise in Resistant Depression, CHU de Toulouse
(University Hospital Centre), Hôpital Purpan, ToNIC Toulouse NeuroImaging
Centre, Université de Toulouse (Toulouse University), INSERM, UPS, Toulouse,
France.
(3)Fondation FondaMental, Creteil, France.
(4)Fondation FondaMental, Creteil, France; Pole de Psychiatrie Générale et
Universitaire, Centre Expert Dépression Résistante FondaMental, CH Charles
Perrens, Bordeaux, Laboratoire Nutrition et Neurobiologie integree (Integrated
Nutrition and Neurobiology Laboratory) (UMR INRAE 1286), Université de Bordeaux
(Bordeaux University), Bordeaux, France.
(5)Fondation FondaMental, Creteil, France; Service de Psychiatrie, Centre Expert
Dépression Résistante FondaMental, CIC-1431 INSERM, CHU de Besançon, Université
de Bourgogne Franche Comté, Besançon, France.
(6)Fondation FondaMental, Creteil, France; AP-HP, GH
Saint-Louis-Lariboisière-Fernand Widal, Pole Neurosciences Tête et Cou (Head and
Neck Neurosciences Cluster), University Paris Diderot, Paris, France.
(7)Fondation FondaMental, Creteil, France; Université Grenoble Alpes, Inserm,
U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences (Institute of
Neurosciences), Grenoble, France.
(8)Fondation FondaMental, Creteil, France; U1253, iBrain, CIC1415, Inserm, CHRU
de Tours (Regional University Hospital Centre), Université de Tours, Tours,
France.
(9)Fondation FondaMental, Creteil, France; Department of Emergency Psychiatry
and Acute Care, CHU Montpellier, INSERM U1061, Montpellier University,
Montpellier, France.
(10)U1253, iBrain, CIC1415, Inserm, CHRU de Tours (Regional University Hospital
Centre), Université de Tours, Tours, France.
(11)Fondation FondaMental, Creteil, France; Université Paris-Est, UMR_S955,
UPEC, Créteil, France Inserm, U955, Equipe 15 Psychiatrie génétique (Team 15
Genetic Psychiatry), Créteil, France AP-HP, Hôpital H. Mondor-A. Chenevier, Pole
de psychiatrie (Psychiatry Cluster), Créteil, France Fondation FondaMental,
Fondation de Coopération Scientifique (Scientific Cooperation Foundation),
Créteil, France.
(12)Fondation FondaMental, Creteil, France; Service de Psychiatrie adulte
(Department of Adult Psychiatry), Centre Expert Dépression Résistante
FondaMental, CHRU de Lille, Hôpital Fontan 1,Lille,France.
(13)Fondation FondaMental, Creteil, France; Department of Psychiatry, CHU
Clermont-Ferrand, University of Clermont Auvergne, Clermont-Ferrand, France.
(14)Fondation FondaMental, Creteil, France; INSERM U1028; CNRS UMR5292;
University Lyon 1, Villeurbanne F-69000, France; Lyon Neuroscience Research
Centre; Psychiatric Disorders: From Resistance to Response ΨR2 Team; Centre
Hospitalier LeVinatier (Hospital Centre); Bron, France.
(15)Fondation FondaMental, Creteil, France; Service Hospitalo-Universitaire de
Psychiatrie Générale et de Réhabilitation Psycho-Sociale 29G01 et 29G02
(University Hospital Department of General Psychiatry and Psychosocial
Rehabilitation), Centre Expert Dépression Résistante FondaMental, CHRU de Brest,
Hôpital de Bohars, Brest, France.
(16)Fondation FondaMental, Creteil, France; Centre National de Ressources et
Résilience pour les psychotraumatismes (National Resilience and Resources Centre
for Psychological Trauma), Lille, France.
(17)Fondation FondaMental, Creteil, France; Marseille Univ, Faculté de Médecine
– Secteur Timone, EA 3279: Service d’Epidemiologie et d’Economie de la Santé,
Unité de Recherche Clinique, Direction de la Recherche en Santé, 27 Boulevard
Jean Moulin, 13005 Marseille, France.
(18)Fondation FondaMental, Creteil, France; Aix-Marseille university, AP-HM,
Academic department of psychiatry, Resistant Depression Expert Center
(FondaMental Foundation), CHU La Conception, Marseille, France. Electronic
address: .
BACKGROUND: Tobacco smoking has been associated with suicide, impulsivity and
depression in non-clinical populations with differences across sexes.
OBJECTIVE: To determine the role of tobacco smoking in Treatment-Resistant
Depression (TRD) according to sex in a precision-medicine approach.
METHOD: The FACE-TRD cohort is a national cohort of TRD patients recruited in 13
resistant depression expert centers between 2014 and 2021 and followed-up at
6 months. A standardized one-day long comprehensive battery was carried out,
including trained-clinician and patient-reported outcomes, and patients were
reevaluated at 6 months on their smoking and psychiatric hospitalization
outcomes.
RESULTS: 355 TRD participants were included (222 women). The smoking rate was
much higher in TRD women compared to the French general population (34% vs 24%)
while it was comparable for men (approximately 29%). In multivariate analyses,
compared to non-smoking women, female smokers had significantly increased number
of lifetime psychiatric hospitalizations (standardized beta B = 0.232,
p = 0.014) and electro-convulsive therapy (adjusted odds ratio (aOR) = 2.748,
p = 0.005), increased suicidal ideations (aOR = 4.047, p = 0.031), history of
suicide attempt (aOR = 1.994, p = 0.033), and increased impulsivity (B = 0.210,
p = 0.006) and were more frequently treated by benzodiazepines (aOR = 1.848,
p = 0.035) and third- or fourth-line TRD treatments (antipsychotics aOR = 2.270,
p = 0.006, mood stabilizers aOR = 2.067 p = 0.044). Tobacco smoking at baseline
was predictive of psychiatric hospitalization within 6 months in persistent
smoking women (aOR = 2.636, p = 0.031). These results were not replicated in
men, for whom tobacco smoking was only associated with increased clinician-rated
and self-reported depressive symptoms (respectively B = 0.207, p = 0.022 and
B = 0.184, p = 0.048). The smoking cessation rate at 6 months was higher in
women than in men (12% vs. 7%). No patient was administered nicotine substitute
or varenicline at the two timepoints.
INTERPRETATION: Combining these results and those of the literature, we
recommend that active tobacco cessation should be promoted in TRD to improve
depression, suicide and impulsivity especially in women. Female smokers appear
as a specific population with heavier mental health outcomes that should be
specifically addressed.
Copyright © 2021 Elsevier Inc. All rights reserved.
DOI: 10.1016/j.pnpbp.2021.110479
PMID: 34826559 [Indexed for MEDLINE]